Tetsuo Shimizu

Dr. Tetsuo Shimizu

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
SSSotaro Shikano
Sotaro Shikano
YGYasuhiro Gon
Yasuhiro Gon
SMShuichiro Maruoka
Shuichiro Maruoka
TSTetsuo Shimizu
Tetsuo Shimizu
YKYutaka Kozu
Yutaka Kozu
SHShu Hashimoto
Shu Hashimoto
Acute respiratory distress syndrome (ARDS) is a life-threatening disease; however, its treatment has not yet been fully established. The progression of ARDS is considered to be mediated by altered intercellular communication between immune and structural cells in the lung. One of several factors involved in intercellular communication is the extracellular vesicle (EV). They act as carriers of functional content such as RNA molecules, proteins, and lipids and deliver cargo from donor to recipient cells. EVs have been reported to regulate the nucleotide-binding oligomerization like receptor 3 (NLRP3) inflammasome. This has been identified as the cellular machinery responsible for activating inflammatory processes, a key component responsible for the pathogenesis of ARDS. Here, we provide comprehensive genetic analysis of microRNAs (miRNAs) in EVs, demonstrating increased expression of the miRNA-466 family in the bronchoalveolar lavage fluid of a mouse ARDS model. Transfection of bone marrow-derived macrophages (BMDMs) with miRNA-466 g and 466 m-5p resulted in increased interleukin-1 beta (IL-1β) release after LPS and ATP treatment, which is an established in vitro model of NLRP3 inflammasome activation. Moreover, LPS-induced pro-IL-1β expression was accelerated by miRNA-466 g and 466 m-5p in BMDMs. These findings imply that miRNA-466 family molecules are secreted via EVs into the airways in an ARDS model, and this exacerbates inflammation through the NLRP3 inflammasome. Our results suggest that the NLRP3 inflammasome pathway, regulated by extracellular vesicle miRNA, could act as a therapeutic target for ARDS.


29 July 2015 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
TSTetsuo Shimizu
Tetsuo Shimizu
YNY. Nakagawa
Y. Nakagawa
NTN. Takahashi
N. Takahashi
SHS. Hashimoto
S. Hashimoto

25 January 2023 in Thoracic Cancer
Verified
Journal Article
Open access
NMNobuaki Mamesaya
Nobuaki Mamesaya
HKHiroaki Kodama
Hiroaki Kodama
YIYuko Iida
Yuko Iida
HKHaruki Kobayashi
Haruki Kobayashi
RKRyo Ko
Ryo Ko
TTToshiaki Takahashi
Toshiaki Takahashi
Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However, older patients often exhibit poor PS (3, 4), and the treatment effect in them is poorly understood. To determine the therapeutic efficacy and safety of carboplatin plus etoposide therapy for this population, we retrospectively analyzed 63 patients with ES‐SCLC with PS ≥2, aged ≥71 years, who had received first‐line carboplatin plus etoposide therapy. We compared the treatment efficacy and safety in patients with baseline PS 2 versus those with PS 3–4. In the PS 2 (38 patients) and PS ≥3 (25 patients) groups, the overall response rate was 71.1% and 72.0%, median progression‐free survival was 4.6 and 3.1 months, and overall survival was 7.7 and 5.1 months, respectively. PS improved to 0–1 post‐treatment in 65.8% and 48.0% of the patients in the PS 2 and PS ≥3 groups, respectively. Patients with PS ≥3 showing improved PS had a progression‐free survival of 6.1 months. A higher incidence of grade ≥3 decreased neutrophil counts, febrile neutropenia, and treatment‐related death was observed in the PS ≥3 group. The progression‐free survival of patients administered prophylactic granulocyte colony‐stimulating factor (G‐CSF) was 5.2 and 6.1 months in the PS2 and PS ≥3 groups. Overall, carboplatin plus etoposide therapy provided comparable tumor shrinkage, but shorter progression‐free and overall survival in older ES‐SCLC patients with PS ≥3 than in those with PS 2. Thus, supportive care, such as prophylactic G‐CSF administration, may be necessary to ensure safety and survival.

1 February 2020 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TSTetsuo Shimizu
Tetsuo Shimizu
YNYoshiko Nakagawa
Yoshiko Nakagawa
YIYuko Iida
Yuko Iida
KHKentaro Hayashi
Kentaro Hayashi
YSYoshihiro Sato
Yoshihiro Sato
YGYasuhiro Gon
Yasuhiro Gon
We herein report a case of refractory exogenous lipoid pneumonia that was successfully attributed to vegetable oil through a lipidomic analysis of bronchoalveolar lavage fluid (BALF). As a 25-year-old woman diagnosed with lipoid pneumonia experienced repeated exacerbations and improvement, we performed a BALF lipidomic analysis. The major lipid components were oleic acid, linoleic acid, and α-linolenic acid, which are constituents of vegetable oil. She stopped consuming any vegetable oil and has since experienced no instances of lipoid pneumonia relapse. A lipidomic analysis appears to be useful for identifying causative lipids, since patients with lipoid pneumonia are sometimes unaware of aspiration episodes.

6 January 2024 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KWKazushige Wakuda
Kazushige Wakuda
MMMeiko Morita
Meiko Morita
MSMotoki Sekikawa
Motoki Sekikawa
NMNoboru Morikawa
Noboru Morikawa
KMKeita Miura
Keita Miura
TTToshiaki Takahashi
Toshiaki Takahashi